Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.

Lisa A BeckRobert BissonnetteMette DeleuranTakeshi NakaharaRyszard GalusAnna ColemanGuy GherardiJing XiaoRobert DingmanChristine XuElena AvetisovaAriane Dubost-BramaArsalan Shabbir

Published in: JAMA dermatology (2024)

In this study, there was sustained safety and efficacy of continuous long-term dupilumab treatment for adults with moderate to severe AD.

Keyphrases

atopic dermatitis
open label
clinical trial
early onset
high intensity
randomized controlled trial
squamous cell carcinoma
drug induced
phase ii study